IP Library Granted Patent US 12,274,789
Granted Patent B2
US 12,274,789 · App. 17/251,784 · Granted Apr 15, 2025

Oral compositions comprising methylprednisolone sodium succinate

Inventors: Tsampikos Dimitrios Panagiotopoulos (Marousi, GR); Soultana Tziala (Artemida, GR)
Assignee: LABOMED PHARMACEUTICAL COMPANY S.A.
A61K9/19A61K31/573A61K47/10A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,274,789
App. No.
17/251,784
Granted
Apr 15, 2025
Kind
B2
Abstract

Stable, non-caking, pharmaceutical composition in the form of powder for oral solution comprising methylprednisolone sodium succinate and methods of making such compositions. The compositions comprise lyophilized methylprednisolone sodium succinate mixed with one or more water-soluble pharmaceutically acceptable excipients.

Claims (5)

1. Pharmaceutical composition in the form of powder for reconstitution for oral administration comprising a mixture of buffered lyophilized methylprednisolone sodium succinate and one or more water-soluble pharmaceutically acceptable excipients, wherein the one or more water-soluble pharmaceutically acceptable excipients are not lyophilized and are selected from the group consisting of from 60% to 75% (w/w), diluent, from 0.1 to 0.5% (w/w), sweetener and from 1 to 6% of (w/w) a lubricant.

2. Pharmaceutical composition according to claim 1 , wherein the diluent is mannitol or lactose or sorbitol, the sweetener is sucralose or sodium saccharin and the lubricant is sodium benzoate.

3. Pharmaceutical composition according to claim 1 , wherein the total concentration of the diluent, which is mannitol, lactose or sorbitol is from 60% to 70% (w/w), the total concentration of the sweetener which is sucralose or sodium saccharin is from 0.2% to 4% (w/w) and the total concentration of the lubricant which is sodium benzoate is from 1.5% to 5% (w/w).

4. Pharmaceutical composition according claim 1 , wherein the concentration of methylprednisolone sodium succinate is from 20% to 30% (w/w).

5. Pharmaceutical composition according to claim 1 , wherein the average particle size of the one or more water-soluble pharmaceutically acceptable excipients is from 30 to 100 microns.

Assignments (2)
MERGER Recorded Mar 15, 2022
From: DOCU-MED LIMITED
To: LABOMED PHARMACEUTICAL COMPANY S.A.
Reel/Frame 059264/0316 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2020
From: PANAGIOTOPOULOS, TSAMPIKOS DIMITRIOS; TZIALA, SOULTANA
To: DOCU-MED LIMITED
Reel/Frame 054623/0633 →
Priority Claims (1)
GR 20180100264 · Jun 18, 2018 · national
Continuity (1)
Related Publication 20210161822A1 · Jun 3, 2021
References Cited (15)
US 4587236A · Annen et al. · 1986 [cited by applicant]
US 20070196415A1 · Chen · 2007 [cited by examiner]
CN 1850089A · 2006 [cited by examiner]
CN 102302460A · 2011 [cited by examiner]
CN 102293755A · 2011 [cited by applicant]
CN 102743392A · 2012 [cited by applicant]
CN 103371979A · 2013 [cited by applicant]
CN 104434820 · 2015 [cited by examiner]
CN 104434820A · 2015 [cited by examiner]
TR 201613662A1 · 2018 [cited by examiner]
WO WO2011101734A2 · 2011 [cited by applicant]
Hayball, P.J., et al., “High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response”, Eur. J. Clin. Pharmacol, 42(1): p. 85-82 (1992). [cited by applicant]
Bin Saif, G.A., “Oral mega pulse methylprednisolone in alopecia universalis”, Saudi Med. J., 2006. 27(5): p. 717-20. [cited by applicant]
Bin Saif, G.A., et al., “Efficacy and safety of oral mega pulse methylprednisolone for severe therapy resistant Alopecia areata”, Saudi Med. J., 2012. 33(3): p. 284-91. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority, issued in PCT/EP2019/066022, mailed Nov. 5, 2019; ISA/EP. [cited by applicant]